Takeda Pharmaceutical Co Ltd 2023 IR
The report highlights Takeda's progress in fiscal year 2022, focusing on its corporate philosophy imperatives of Patient, People, and Planet. Key achievements include the approval of its dengue vaccine, QDENGA, in the European Union and other countries, and reaching its plasma supply capacity target one year early. The company delivered core revenue growth of 3.5% at constant exchange rates, totaling 4,027.5 billion yen. Takeda also accelerated its climate goals, committing to net-zero greenhouse gas emissions in its operations by 2035 and across its entire value chain by 2040.
Company: Takeda Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 60
Takeda Pharmaceutical Co Ltd
Annual Integrated Report
The report highlights Takeda's progress in fiscal year 2022, focusing on its corporate philosophy imperatives of Patient, People, and Planet. Key achievements include the approval of its dengue vaccine, QDENGA, in the European Union and other countries, and reaching its plasma supply capacity target one year early. The company delivered core revenue growth of 3.5% at constant exchange rates, totaling 4,027.5 billion yen. Takeda also accelerated its climate goals, committing to net-zero greenhouse gas emissions in its operations by 2035 and across its entire value chain by 2040.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Net Zero Target
Employees